BACKGROUND: Angiotensin-converting enzyme 2 (ACE2), an ACE homolog, hydrolyzes angiotensin II and opposes its actions, and plays a protective role in the pathogenesis of pulmonary arterial hypertension (PAH). However, the underlying mechanisms involved in the effect of ACE2 on PAH are still uncertain. In this study, we observed the effects of ACE2 activation on endothelial dysfunction and vascular remodeling in the development of severe PAH in rats. METHODS: Severe PAH was induced by monocrotaline injection 1 week following left pneumonectomy, and ACE2 was activated by continuous injection of resorcinolnaphthalein. The PAH-related hemodynamics, pathological changes, and endothelium-dependent vasorelaxation were examined to assess the effects of ACE2 activation. In addition, the changes of the main components of the renin-angiotensin system were identified by ELISA or Western blotting. RESULTS: Severe PAH was established at 3 weeks and was characterized by high pulmonary arterial pressure (45 mmHg), significant right ventricular hypertrophy, neointimal occlusive lesions, and impaired endothelium-dependent relaxation in pulmonary arteries. Coadministration of resorcinolnaphthalein reduced pulmonary arterial pressure, right ventricular hypertrophy, and neointimal formation and shifted the endothelial-dependent responses toward values measured in normal rats. Theses changes were associated with an increase in ACE2 and angiotensin-(1-7) levels and a decrease in ACE and angiotensin II levels, in addition to a decrease in the ACE/ACE2 ratio and the angiotensin II/angiotensin-(1-7) ratio. The beneficial effects of resorcinolnaphthalein were abolished by A-779. CONCLUSIONS: These findings suggested that ACE2 activation by resorcinolnaphthalein improved endothelial function and suppressed neointimal formation in the prevention of severe PAH by the mechanism of mediating the levels of the components of the renin-angiotensin system.
BACKGROUND:Angiotensin-converting enzyme 2 (ACE2), an ACE homolog, hydrolyzes angiotensin II and opposes its actions, and plays a protective role in the pathogenesis of pulmonary arterial hypertension (PAH). However, the underlying mechanisms involved in the effect of ACE2 on PAH are still uncertain. In this study, we observed the effects of ACE2 activation on endothelial dysfunction and vascular remodeling in the development of severe PAH in rats. METHODS: Severe PAH was induced by monocrotaline injection 1 week following left pneumonectomy, and ACE2 was activated by continuous injection of resorcinolnaphthalein. The PAH-related hemodynamics, pathological changes, and endothelium-dependent vasorelaxation were examined to assess the effects of ACE2 activation. In addition, the changes of the main components of the renin-angiotensin system were identified by ELISA or Western blotting. RESULTS: Severe PAH was established at 3 weeks and was characterized by high pulmonary arterial pressure (45 mmHg), significant right ventricular hypertrophy, neointimal occlusive lesions, and impaired endothelium-dependent relaxation in pulmonary arteries. Coadministration of resorcinolnaphthalein reduced pulmonary arterial pressure, right ventricular hypertrophy, and neointimal formation and shifted the endothelial-dependent responses toward values measured in normal rats. Theses changes were associated with an increase in ACE2 and angiotensin-(1-7) levels and a decrease in ACE and angiotensin II levels, in addition to a decrease in the ACE/ACE2 ratio and the angiotensin II/angiotensin-(1-7) ratio. The beneficial effects of resorcinolnaphthalein were abolished by A-779. CONCLUSIONS: These findings suggested that ACE2 activation by resorcinolnaphthalein improved endothelial function and suppressed neointimal formation in the prevention of severe PAH by the mechanism of mediating the levels of the components of the renin-angiotensin system.
Authors: Cheng Zhang; Yu Xia Zhao; Yue Hui Zhang; Li Zhu; Bi Ping Deng; Zhao Li Zhou; Shu Ying Li; Xiao Ting Lu; Li Li Song; Xue Ming Lei; Wen Bo Tang; Nan Wang; Chun Ming Pan; Huai Dong Song; Chun Xi Liu; Bo Dong; Yun Zhang; Yihai Cao Journal: Proc Natl Acad Sci U S A Date: 2010-08-23 Impact factor: 11.205
Authors: José A Hernández Prada; Anderson J Ferreira; Michael J Katovich; Vinayak Shenoy; Yanfei Qi; Robson A S Santos; Ronald K Castellano; Andrew J Lampkins; Vladimir Gubala; David A Ostrov; Mohan K Raizada Journal: Hypertension Date: 2008-04-07 Impact factor: 10.190
Authors: Douglas M Bennion; Emily Haltigan; Robert W Regenhardt; U Muscha Steckelings; Colin Sumners Journal: Curr Hypertens Rep Date: 2015-02 Impact factor: 5.369
Authors: Shanshan Qin; Dan N Predescu; Monal Patel; Patrick Drazkowski; Balaji Ganesh; Sanda A Predescu Journal: J Cell Sci Date: 2020-05-14 Impact factor: 5.285
Authors: Matthew K Hensley; Andrea Levine; Mark T Gladwin; Yen-Chun Lai Journal: Am J Physiol Lung Cell Mol Physiol Date: 2018-02-01 Impact factor: 5.464
Authors: Ravindra K Sharma; Aline C Oliveira; Tao Yang; Marianthi M Karas; Jing Li; Gilberto O Lobaton; Victor P Aquino; Iñaki Robles-Vera; Annette D de Kloet; Eric G Krause; Andrew J Bryant; Amrisha Verma; Qiuhong Li; Elaine M Richards; Mohan K Raizada Journal: Hypertension Date: 2020-05-18 Impact factor: 10.190
Authors: Shanshan Qin; Dan Predescu; Brandon Carman; Priyam Patel; Jiwang Chen; Miran Kim; Tim Lahm; Mark Geraci; Sanda A Predescu Journal: Am J Pathol Date: 2021-04-06 Impact factor: 5.770